{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T06:28:08Z","timestamp":1762928888516,"version":"3.37.3"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"17-18","license":[{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00508-021-01855-6","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T06:03:24Z","timestamp":1618898604000},"page":"983-988","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19\u00a0patients"],"prefix":"10.1007","volume":"133","author":[{"given":"Antonio","family":"Vitiello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9298-6783","authenticated-orcid":false,"given":"Francesco","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"issue":"21","key":"1855_CR1","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1056\/NEJMoa2005412","volume":"382","author":"TM McMichael","year":"2020","unstructured":"McMichael\u00a0TM, Currie\u00a0DW, Clark\u00a0S, Pogosjans\u00a0S, Kay\u00a0M, Schwartz\u00a0NG, et al. Public health\u2014seattle and king county, evergreenhealth, and CDC COVID-19 investigation team. Epidemiology of Covid-19 in a\u00a0long-term care facility in king county, washington. N\u00a0Engl J Med. 2020;382(21):2005\u201311. https:\/\/doi.org\/10.1056\/NEJMoa2005412.","journal-title":"N Engl J Med"},{"key":"1855_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11845-020-02401-5","volume":"17","author":"F Ferrara","year":"2020","unstructured":"Ferrara\u00a0F, Porta\u00a0R, D\u2019Aiuto\u00a0V, Vitiello\u00a0A. Remdesivir and COVID-19. Ir J Med Sci. 2020;17:1\u20132. https:\/\/doi.org\/10.1007\/s11845-020-02401-5.","journal-title":"Ir J Med Sci"},{"key":"1855_CR3","unstructured":"World health organization (WHO). Situation Reports July 2020. https:\/\/www.who.int\/emergencies\/diseases\/novelcoronavirus2019\/situation-reports. Accessed 2 March 2021"},{"key":"1855_CR4","volume-title":"StatPearls","author":"M Cascella","year":"2020","unstructured":"Cascella\u00a0M, Rajnik\u00a0M, Cuomo\u00a0A, Dulebohn\u00a0SC, Di Napoli\u00a0R. Features, evaluation, and treatment of Coronavirus. In: StatPearls. 2020."},{"issue":"2","key":"1855_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls\u00a0AC, Park\u00a0YJ, Tortorici\u00a0MA, Wall\u00a0A, McGuire\u00a0AT, Veesler\u00a0D. Structure, function, and antigenicity of the SARS-coV\u20112 spike glycoprotein. Cell. 2020;181(2):281\u2013292.e6. https:\/\/doi.org\/10.1016\/j.cell.2020.02.058.","journal-title":"Cell"},{"issue":"7","key":"1855_CR6","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1001\/jamacardio.2020.0950","volume":"5","author":"S Shi","year":"2020","unstructured":"Shi\u00a0S, Qin\u00a0M, Shen\u00a0B, Cai\u00a0Y, Liu\u00a0T, Yang\u00a0F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802\u201310. https:\/\/doi.org\/10.1001\/jamacardio.2020.0950.","journal-title":"JAMA Cardiol"},{"key":"1855_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-020-02440-y","author":"A Vitiello","year":"2020","unstructured":"Vitiello\u00a0A, Ferrara\u00a0F. Remdesivir versus ritonavir\/lopinavir in COVID-19\u00a0patients. Ir J Med Sci. 2020; https:\/\/doi.org\/10.1007\/s11845-020-02440-y.","journal-title":"Ir J Med Sci"},{"key":"1855_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-020-02482-2","author":"A Vitiello","year":"2021","unstructured":"Vitiello\u00a0A, Ferrara\u00a0F, Porta\u00a0R. Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks? Ir J Med Sci. 2021; https:\/\/doi.org\/10.1007\/s11845-020-02482-2.","journal-title":"Ir J Med Sci"},{"key":"1855_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-021-02049-7","author":"F Ferrara","year":"2021","unstructured":"Ferrara\u00a0F, Vitiello\u00a0A. Efficacy of synthetic glucocorticoids in COVID-19 endothelites. Naunyn Schmiedebergs Arch Pharmacol. 2021; https:\/\/doi.org\/10.1007\/s00210-021-02049-7.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1855_CR10","doi-asserted-by":"publisher","unstructured":"Vitiello A, La Porta R, D\u2019Aiuto V, Ferrara F. Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Hum Immunol. 2021;S0198-8859(21)00014-8. https:\/\/doi.org\/10.1016\/j.humimm.2021.01.007.","DOI":"10.1016\/j.humimm.2021.01.007"},{"key":"1855_CR11","doi-asserted-by":"publisher","unstructured":"Vitiello A, Pelliccia C, Ferrara F. Drugs acting on the renin-angiotensin system and SARS-CoV-2. Drug Discov Today. 2021;S1359-6446(21)00037-4. https:\/\/doi.org\/10.1016\/j.drudis.2021.01.010.","DOI":"10.1016\/j.drudis.2021.01.010"},{"issue":"6","key":"1855_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.tips.2004.04.001","volume":"25","author":"AJ Turner","year":"2004","unstructured":"Turner\u00a0AJ, Hiscox\u00a0JA, Hooper\u00a0NM. ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci. 2004;25(6):291\u20134. https:\/\/doi.org\/10.1016\/j.tips.2004.04.001.","journal-title":"Trends Pharmacol Sci"},{"issue":"20","key":"1855_CR13","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1001\/jama.2020.6775","volume":"323","author":"S Richardson","year":"2020","unstructured":"Richardson\u00a0S, Hirsch\u00a0JS, Narasimhan\u00a0M, Crawford\u00a0JM, McGinn\u00a0T, Davidson\u00a0KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA. 2020;323(20):2052\u20139. https:\/\/doi.org\/10.1001\/jama.2020.6775.","journal-title":"JAMA"},{"issue":"7","key":"1855_CR14","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jamacardio.2020.1017","volume":"5","author":"T Guo","year":"2020","unstructured":"Guo\u00a0T, Fan\u00a0Y, Chen\u00a0M, Wu\u00a0X, Zhang\u00a0L, He\u00a0T, et al. Cardiovascular implications of fatal outcomes of patients with Coronavirus disease 2019 (COVID-19). JAMA. 2020;5(7):811\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2020.1017.","journal-title":"JAMA"},{"issue":"10229","key":"1855_CR15","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou\u00a0F, Yu\u00a0T, Du\u00a0R, Fan\u00a0G, Liu\u00a0Y, Liu\u00a0Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a\u00a0retrospective cohort study. Lancet. 2020;395(10229):1054\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(20)30566-3.","journal-title":"Lancet"},{"issue":"5","key":"1855_CR16","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","volume":"46","author":"Q Ruan","year":"2020","unstructured":"Ruan\u00a0Q, Yang\u00a0K, Wang\u00a0W, Jiang\u00a0L, Song\u00a0J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150\u00a0patients from Wuhan, China. Intensive Care Med. 2020;46(5):846\u20138. https:\/\/doi.org\/10.1007\/s00134-020-05991-x.","journal-title":"Intensive Care Med"},{"issue":"2","key":"1855_CR17","first-page":"88","volume":"14","author":"A Vitiello","year":"2020","unstructured":"Vitiello\u00a0A, Ferrara\u00a0F, Pelliccia\u00a0C, Granata\u00a0G, La Porta\u00a0R. Cytokine storm and colchicine potential role in fighting SARS-CoV\u20112 pneumonia. Ital J Med. 2020;14(2):88\u201394.","journal-title":"Ital J Med"},{"key":"1855_CR18","doi-asserted-by":"publisher","unstructured":"Ferrara F, Granata G, Pelliccia C, La Porta R, Vitiello A. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? Eur J Clin Pharmacol. 2020;76(11):1615\u20131618. https:\/\/doi.org\/10.1007\/s00228-020-02947-4.","DOI":"10.1007\/s00228-020-02947-4"},{"key":"1855_CR19","doi-asserted-by":"publisher","first-page":"173373","DOI":"10.1016\/j.ejphar.2020.173373","volume":"883","author":"A Vitiello","year":"2020","unstructured":"Vitiello\u00a0A, Ferrara\u00a0F. Correlation between renin-angiotensin system and severe acute respiratory syndrome Coronavirus 2 infection: what do we know? Eur J Pharmacol. 2020;883:173373. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173373.","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"1855_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00281-017-0629-x","volume":"39","author":"R Channappanavar","year":"2017","unstructured":"Channappanavar\u00a0R, Perlman\u00a0S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529\u201339. https:\/\/doi.org\/10.1007\/s00281-017-0629-x.","journal-title":"Semin Immunopathol"},{"issue":"1","key":"1855_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1128\/MMBR.05015-11","volume":"76","author":"JR Tisoncik","year":"2012","unstructured":"Tisoncik\u00a0JR, Korth\u00a0MJ, Simmons\u00a0CP, Farrar\u00a0J, Martin\u00a0TR, Katze\u00a0MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76(1):16\u201332. https:\/\/doi.org\/10.1128\/MMBR.05015-11.","journal-title":"Microbiol Mol Biol Rev"},{"issue":"4","key":"1855_CR22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1161\/01.res.81.4.493","volume":"81","author":"CF McTiernan","year":"1997","unstructured":"McTiernan\u00a0CF, Lemster\u00a0BH, Frye\u00a0C, Brooks\u00a0S, Combes\u00a0A, Feldman\u00a0AM. Interleukin\u20111 beta inhibits phospholamban gene expression in cultured cardiomyocytes. Circ Res. 1997;81(4):493\u2013503. https:\/\/doi.org\/10.1161\/01.res.81.4.493.","journal-title":"Circ Res"},{"issue":"17","key":"1855_CR23","doi-asserted-by":"publisher","first-page":"6753","DOI":"10.1073\/pnas.86.17.6753","volume":"86","author":"T Gulick","year":"1989","unstructured":"Gulick\u00a0T, Chung\u00a0MK, Pieper\u00a0SJ, Lange\u00a0LG, Schreiner\u00a0GF. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci U S\u00a0A. 1989;86(17):6753\u20137. https:\/\/doi.org\/10.1073\/pnas.86.17.6753.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10223","key":"1855_CR24","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang\u00a0C, Wang\u00a0Y, Li\u00a0X, Ren\u00a0L, Zhao\u00a0J, Hu\u00a0Y, et\u00a0al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497\u2013506. https:\/\/doi.org\/10.1016\/S0140-6736(20)30183-5.","journal-title":"Lancet"},{"issue":"5","key":"1855_CR25","doi-asserted-by":"publisher","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","volume":"55","author":"C Zhang","year":"2020","unstructured":"Zhang\u00a0C, Wu\u00a0Z, Li\u00a0JW, Zhao\u00a0H, Wang\u00a0GQ. Cytokine release syndrome in severe COVID-19: interleukin\u20116 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105954.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"1855_CR26","doi-asserted-by":"publisher","first-page":"114","DOI":"10.4081\/itjm.2020.1290","volume":"14","author":"F Ferrara","year":"2020","unstructured":"Ferrara\u00a0F. Antirheumatic in SARS-CoV-2: benefit or risk? Ital J Med. 2020;14(2):114\u20135. https:\/\/doi.org\/10.4081\/itjm.2020.1290.","journal-title":"Ital J Med"},{"key":"1855_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.peptides.2012.12.010","volume":"40","author":"S Del Ry","year":"2013","unstructured":"Del Ry\u00a0S. C\u2011type natriuretic peptide: a\u00a0new cardiac mediator. Peptides. 2013;40:93\u20138. https:\/\/doi.org\/10.1016\/j.peptides.2012.12.010.","journal-title":"Peptides"},{"issue":"1","key":"1855_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/sj.bjp.0707476","volume":"153","author":"V Leuranguer","year":"2008","unstructured":"Leuranguer\u00a0V, Vanhoutte\u00a0PM, Verbeuren\u00a0T, F\u00e9l\u00e9tou\u00a0M. C\u2011type natriuretic peptide and endothelium-dependent hyperpolarization in the guinea-pig carotid artery. Br J Pharmacol. 2008;153(1):57\u201365. https:\/\/doi.org\/10.1038\/sj.bjp.0707476.","journal-title":"Br J Pharmacol"},{"issue":"8","key":"1855_CR29","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.peptides.2011.06.014","volume":"32","author":"S Del Ry","year":"2011","unstructured":"Del Ry\u00a0S, Cabiati\u00a0M, Vozzi\u00a0F, Battolla\u00a0B, Caselli\u00a0C, Forini\u00a0F, et al. Expression of C\u2011type natriuretic peptide and its receptor NPR\u2011B in cardiomyocytes. Peptides. 2011;32(8):1713\u20138. https:\/\/doi.org\/10.1016\/j.peptides.2011.06.014.","journal-title":"Peptides"},{"issue":"1","key":"1855_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/bbrc.1996.0836","volume":"223","author":"M Suda","year":"1996","unstructured":"Suda\u00a0M, Tanaka\u00a0K, Fukushima\u00a0M, Natsui\u00a0K, Yasoda\u00a0A, Komatsu\u00a0Y, et al. C\u2011type natriuretic peptide as an autocrine\/paracrine regulator of osteoblast. Evidence for possible presence of bone natriuretic peptide system. Biochem Biophys Res Commun. 1996;223(1):1\u20136. https:\/\/doi.org\/10.1006\/bbrc.1996.0836.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"1855_CR31","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jacc.2004.10.067","volume":"45","author":"T Soeki","year":"2005","unstructured":"Soeki\u00a0T, Kishimoto\u00a0I, Okumura\u00a0H, Tokudome\u00a0T, Horio\u00a0T, Mori\u00a0K, et al. C\u2011type natriuretic peptide, a\u00a0novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J\u00a0Am Coll Cardiol. 2005;45(4):608\u201316. https:\/\/doi.org\/10.1016\/j.jacc.2004.10.067.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1855_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/art.38199","volume":"66","author":"H B\u00fck\u00fclmez","year":"2014","unstructured":"B\u00fck\u00fclmez\u00a0H, Khan\u00a0F, Bartels\u00a0CF, Murakami\u00a0S, Ortiz-Lopez\u00a0A, Sattar\u00a0A, et al. Protective effects of C\u2011type natriuretic peptide on linear growth and articular cartilage integrity in a\u00a0mouse model of inflammatory arthritis. Arthritis Rheumatol. 2014;66(1):78\u201389. https:\/\/doi.org\/10.1002\/art.38199.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1855_CR33","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jss.2014.11.023","volume":"194","author":"T Kimura","year":"2015","unstructured":"Kimura\u00a0T, Nojiri\u00a0T, Hosoda\u00a0H, Ishikane\u00a0S, Shintani\u00a0Y, Inoue\u00a0M, et al. C\u2011type natriuretic peptide attenuates lipopolysaccharide-induced acute lung injury in mice. J\u00a0Surg Res. 2015;194(2):631\u20137. https:\/\/doi.org\/10.1016\/j.jss.2014.11.023.","journal-title":"J Surg Res"},{"key":"1855_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1990.","author":"JR Rey","year":"2020","unstructured":"CARD-COVID Investigators, Rey\u00a0JR, Caro-Cod\u00f3n\u00a0J, Rosillo\u00a0SO, Iniesta \u00c1M, Castrej\u00f3n-Castrej\u00f3n\u00a0S et al. Heart failure in COVID-19\u00a0patients: prevalence, incidence and prognostic implications. Eur J Heart Fail. 2020; https:\/\/doi.org\/10.1002\/ejhf.1990.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"1855_CR35","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3892\/mmr.2014.2763","volume":"11","author":"ZQ Li","year":"2015","unstructured":"Li\u00a0ZQ, Liu\u00a0YL, Li\u00a0G, Li\u00a0B, Liu\u00a0Y, Li\u00a0XF, et al. Inhibitory effects of C\u2011type natriuretic peptide on the differentiation of cardiac fibroblasts, and secretion of monocyte chemoattractant protein\u20111 and plasminogen activator inhibitor\u20111. Mol Med Rep. 2015;11(1):159\u201365. https:\/\/doi.org\/10.3892\/mmr.2014.2763.","journal-title":"Mol Med Rep"},{"issue":"1","key":"1855_CR36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12931-016-0429-1","volume":"17","author":"T Kimura","year":"2016","unstructured":"Kimura\u00a0T, Nojiri\u00a0T, Hino\u00a0J, Hosoda\u00a0H, Miura\u00a0K, Shintani\u00a0Y, et al. Erratum to: C\u2011type natriuretic peptide ameliorates pulmonary fibrosis by acting on lung fibroblasts in mice. Respir Res. 2016;17(1):113. https:\/\/doi.org\/10.1186\/s12931-016-0429-1.","journal-title":"Respir Res"},{"key":"1855_CR37","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/5858315","author":"L Mezzasoma","year":"2017","unstructured":"Mezzasoma\u00a0L, Antognelli\u00a0C, Talesa\u00a0VN. A novel role for brain natriuretic peptide: inhibition of IL-1\u03b2 secretion via downregulation of NF-kB\/Erk 1\/2 and NALP3\/ASC\/Caspase\u20111 activation in human THP\u20111 monocyte. Mediators Inflamm. 2017; https:\/\/doi.org\/10.1155\/2017\/5858315.","journal-title":"Mediators Inflamm"},{"issue":"6","key":"1855_CR38","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1136\/hrt.2005.071233","volume":"92","author":"M Weber","year":"2006","unstructured":"Weber\u00a0M, Hamm\u00a0C. Role of B\u2011type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 2006;92(6):843\u20139. https:\/\/doi.org\/10.1136\/hrt.2005.071233.","journal-title":"Heart"},{"issue":"8","key":"1855_CR39","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1042\/CS20120081","volume":"123","author":"D Shrikrishna","year":"2012","unstructured":"Shrikrishna\u00a0D, Astin\u00a0R, Kemp\u00a0PR, Hopkinson\u00a0NS. Renin-angiotensin system blockade: a\u00a0novel therapeutic approach in chronic obstructive pulmonary disease. Clin Sci. 2012;123(8):487\u201398. https:\/\/doi.org\/10.1042\/CS20120081.","journal-title":"Clin Sci"},{"key":"1855_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105223","author":"D Mei","year":"2020","unstructured":"Mei\u00a0D, Tan\u00a0WSD, Liao\u00a0W, Heng\u00a0CKM, Wong\u00a0WSF. Activation of angiotensin II type\u20112 receptor protects against cigarette smoke-induced COPD. Pharmacol Res. 2020; https:\/\/doi.org\/10.1016\/j.phrs.2020.105223.","journal-title":"Pharmacol Res"},{"issue":"19","key":"1855_CR41","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1093\/eurheartj\/ehaa311","volume":"41","author":"L Nicin","year":"2020","unstructured":"Nicin\u00a0L, Abplanalp\u00a0WT, Mellentin\u00a0H, Kattih\u00a0B, Tombor\u00a0L, John\u00a0D, et al. Cell type-specific expression of the putative SARS-CoV\u20112 receptor ACE2 in human hearts. Eur Heart\u00a0J. 2020;41(19):1804\u20136. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa311.","journal-title":"Eur Heart J"},{"key":"1855_CR42","doi-asserted-by":"publisher","DOI":"10.4081\/itjm.2020.1435","author":"F Ferrara","year":"2020","unstructured":"Ferrara\u00a0F, Vitiello\u00a0A. Potenzial pharmacological approach in the regulation of ACE\u20112 and DPP-IV in diabetic COVID-19\u00a0patient. Ital J Med. 2020; https:\/\/doi.org\/10.4081\/itjm.2020.1435.","journal-title":"Ital J Med"},{"key":"1855_CR43","doi-asserted-by":"publisher","first-page":"118510","DOI":"10.1016\/j.lfs.2020.118510","volume":"262","author":"A Vitiello","year":"2020","unstructured":"Vitiello\u00a0A, Ferrara\u00a0F. Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. Life Sci. 2020;262:118510. https:\/\/doi.org\/10.1016\/j.lfs.2020.118510.","journal-title":"Life Sci"},{"issue":"3","key":"1855_CR44","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s12250-020-00205-6","volume":"35","author":"Y Wu","year":"2020","unstructured":"Wu\u00a0Y. Compensation of ACE2 function for possible clinical management of 2019-nCoV-induced acute lung injury. Virol Sin. 2020;35(3):256\u20138. https:\/\/doi.org\/10.1007\/s12250-020-00205-6.","journal-title":"Virol Sin"},{"issue":"1","key":"1855_CR45","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.atherosclerosis.2006.10.013","volume":"194","author":"A Recinos 3rd","year":"2007","unstructured":"Recinos\u00a0A 3rd, LeJeune\u00a0WS, Sun\u00a0H, Lee\u00a0CY, Tieu\u00a0BC, Lu\u00a0M, et al. Angiotensin II induces IL\u20116 expression and the Jak-STAT3 pathway in aortic adventitia of LDL receptor-deficient mice. Atherosclerosis. 2007;194(1):125\u201333. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2006.10.013.","journal-title":"Atherosclerosis"},{"key":"1855_CR46","first-page":"125","volume":"3","author":"C Schindler","year":"2007","unstructured":"Schindler\u00a0C, Bramlage\u00a0P, Kirch\u00a0W, Ferrario\u00a0CM. Role of the vasodilator peptide angiotensin-(1\u20137) in cardiovascular drug therapy. Vasc Health Risk Manag. 2007;3:125\u201337.","journal-title":"Vasc Health Risk Manag"},{"issue":"7047","key":"1855_CR47","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai\u00a0Y, Kuba\u00a0K, Rao\u00a0S, Huan\u00a0Y, Guo\u00a0F, Guan\u00a0B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112\u20136. https:\/\/doi.org\/10.1038\/nature03712.","journal-title":"Nature"},{"issue":"6","key":"1855_CR48","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/ejhf.1871","volume":"22","author":"D Tomasoni","year":"2020","unstructured":"Tomasoni\u00a0D, Italia\u00a0L, Adamo\u00a0M, Inciardi\u00a0RM, Lombardi\u00a0CM, Solomon\u00a0SD, et al. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a\u00a0new disease. Eur J Heart Fail. 2020;22(6):957\u201366. https:\/\/doi.org\/10.1002\/ejhf.1871.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"1855_CR49","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","volume":"133","author":"SA Hubers","year":"2016","unstructured":"Hubers\u00a0SA, Brown\u00a0NJ. Combined angiotensin receptor antagonism and Neprilysin inhibition. Circulation. 2016;133(11):1115\u201324. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018622.","journal-title":"Circulation"},{"key":"1855_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2020-111497","author":"A Vitiello","year":"2020","unstructured":"Vitiello\u00a0A, La Porta\u00a0R, Ferrara\u00a0F. Sacubitril, valsartan and SARS-CoV\u20112. BMJ Evid Based Med. 2020; https:\/\/doi.org\/10.1136\/bmjebm-2020-111497.","journal-title":"BMJ Evid Based Med"},{"key":"1855_CR51","doi-asserted-by":"publisher","first-page":"105579","DOI":"10.1016\/j.ejps.2020.105579","volume":"156","author":"A Vitiello","year":"2020","unstructured":"Vitiello\u00a0A, Ferrara\u00a0F. Therapeutic strategies for SARS-coV\u20112 acting on ACE\u20112. Eur J Pharm Sci. 2020;156:105579. https:\/\/doi.org\/10.1016\/j.ejps.2020.105579.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"1855_CR52","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/s13054-020-03120-0","volume":"24","author":"W Ni","year":"2020","unstructured":"Ni\u00a0W, Yang\u00a0X, Yang\u00a0D, Bao\u00a0J, Li\u00a0R, Xiao\u00a0Y, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020;24(1):422.","journal-title":"Crit Care"},{"key":"1855_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2021.110486","author":"A Vitiello","year":"2021","unstructured":"Vitiello\u00a0A, La Porta\u00a0R, Ferrara\u00a0F. Scientific hypothesis and rational pharmacological for the use of sacubitril\/valsartan in cardiac damage caused by COVID-19. Med Hypotheses. 2021; https:\/\/doi.org\/10.1016\/j.mehy.2021.110486.","journal-title":"Med Hypotheses"},{"key":"1855_CR54","doi-asserted-by":"publisher","unstructured":"Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, et al. The ACE2\/Angiotensin-(1-7)\/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7). American Journal of Physiology-Heart and Circulatory Physiology. https:\/\/doi.org\/10.1152\/physrev.00023.2016.","DOI":"10.1152\/physrev.00023.2016"},{"issue":"8","key":"1855_CR55","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1161\/CIRCRESAHA.116.307708","volume":"118","author":"VB Patel","year":"2016","unstructured":"Patel\u00a0VB, Zhong\u00a0JC, Grant\u00a0MB, Oudit\u00a0GY. Role of the ACE2\/Angiotensin 1\u20137 axis of the Renin-Angiotensin system in heart failure. Circ Res. 2016;118(8):1313\u201326. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.307708.","journal-title":"Circ Res"},{"issue":"4","key":"1855_CR56","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1165\/rcmb.2012-0451OC","volume":"50","author":"Y Meng","year":"2014","unstructured":"Meng\u00a0Y, Yu\u00a0CH, Li\u00a0W, Li\u00a0T, Luo\u00a0W, Huang\u00a0S, et al. Angiotensin-converting enzyme 2\/angiotensin-(1\u20137)\/Mas axis protects against lung fibrosis by inhibiting the MAPK\/NF-\u03baB pathway. Am J Respir Cell Mol Biol. 2014;50(4):723\u201336. https:\/\/doi.org\/10.1165\/rcmb.2012-0451OC.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"1855_CR57","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1161\/01.CIR.0000081768.13378","volume":"108","author":"M Flesch","year":"2003","unstructured":"Flesch\u00a0M, H\u00f6per\u00a0A, Dell\u2019Italia\u00a0L, Evans\u00a0K, Bond\u00a0R, Peshock\u00a0R, et al. Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2003;108(5):598\u2013604. https:\/\/doi.org\/10.1161\/01.CIR.0000081768.13378.","journal-title":"Circulation"},{"issue":"19","key":"1855_CR58","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1093\/eurheartj\/ehaa235","volume":"41","author":"GM Kuster","year":"2020","unstructured":"Kuster\u00a0GM, Pfister\u00a0O, Burkard\u00a0T, Zhou\u00a0Q, Twerenbold\u00a0R, Haaf\u00a0P, et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart\u00a0J. 2020;41(19):1801\u20133. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa235.","journal-title":"Eur Heart J"},{"issue":"5","key":"1855_CR59","doi-asserted-by":"publisher","first-page":"441","DOI":"10.4103\/ijp.IJP_417_20","volume":"52","author":"F Ferrara","year":"2020","unstructured":"Ferrara\u00a0F, Porta\u00a0R, Santilli\u00a0P, D\u2019Aiuto\u00a0V, Vitiello\u00a0A. Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2\u00a0times? Indian J Pharmacol. 2020;52(5):441\u20132. https:\/\/doi.org\/10.4103\/ijp.IJP_417_20.","journal-title":"Indian J Pharmacol"},{"issue":"1","key":"1855_CR60","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40360-018-0207-4","volume":"19","author":"N Lombardi","year":"2018","unstructured":"Lombardi\u00a0N, Crescioli\u00a0G, Bettiol\u00a0A, Marconi\u00a0E, Vitiello\u00a0A, Bonaiuti\u00a0R, et al. Characterization of serious adverse drug reactions as cause of emergency department visit in children: a\u00a05-years active pharmacovigilance study. BMC Pharmacol Toxicol. 2018;19(1):16. https:\/\/doi.org\/10.1186\/s40360-018-0207-4.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"1855_CR61","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/ehjcvp\/pvaa044","volume":"6","author":"D Acanfora","year":"2020","unstructured":"Acanfora\u00a0D, Ciccone\u00a0MM, Scicchitano\u00a0P, Acanfora\u00a0C, Casucci\u00a0G. Sacubitril\/valsartan in COVID-19\u00a0patients: the need for trials. Eur Heart J Cardiovasc Pharmacother. 2020;6(4):253\u20134. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa044.","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-021-01855-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-021-01855-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-021-01855-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T11:20:52Z","timestamp":1631704852000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-021-01855-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":61,"journal-issue":{"issue":"17-18","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1855"],"URL":"https:\/\/doi.org\/10.1007\/s00508-021-01855-6","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"type":"print","value":"0043-5325"},{"type":"electronic","value":"1613-7671"}],"subject":[],"published":{"date-parts":[[2021,4,20]]},"assertion":[{"value":"16 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.\u00a0Vitiello and F.\u00a0Ferrara declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}